T cells redirected to specific antigen targets with engineered chimeric antigen receptors
(CARs) are emerging as powerful therapies in hematologic malignancies. Various CAR …

Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …

Patients with multiply relapsed or refractory chronic lymphocytic leukemia (CLL) have a poor
prognosis. Chimeric antigen receptor (CAR)–modified T cells targeting CD19 have the …

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly
diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic …

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …

Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …

In chronic lymphocytic leukemia (CLL), acquired T-cell dysfunction impedes development of
effective immunotherapeutic strategies, through as-yet unresolved mechanisms. We have …

Blockade of the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1)
immune checkpoint augments antitumor immunity and induces durable responses in …

Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Over the last decade, the emergence of several novel therapeutic approaches has changed
the therapeutic perspective of human malignancies. Adoptive immunotherapy through …